Literature DB >> 10682318

Apoptosis or necrosis for tumor immunotherapy: what's in a name?

A Melcher1, M Gough, S Todryk, R Vile.   

Abstract

Here we discuss how the mechanisms by which tumor cells are killed in vivo by gene transfer affects their immunogenicity. Our own work has shown that necrotic cell death induces immunological activation signals which recruit, load, activate and mature appropriate subsets of antigen-presenting cells. In contrast, for apoptotic cell death to be immunogenic, signals additional to cell death alone must be provided within the milieu of the dying tumor. Our conclusion is that the immunogenicity of tumor killing is determined by a combination of factors, including the mechanism of killing, the levels of cell death, the local environment that exists within the dying tumor and, as a result, the nature of the immune/scavenger cells which are present at the time of antigen release. Knowledge of how these factors can influence the immune system and lead to the breaking of tolerance to tumor-associated antigens, can potentially be exploited in the design of effective immunotherapies for cancer using gene transfer.

Entities:  

Mesh:

Year:  1999        PMID: 10682318     DOI: 10.1007/s001099900066

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  31 in total

1.  Heat shock proteins refine the danger theory.

Authors:  S M Todryk; A A Melcher; A G Dalgleish; R G Vile
Journal:  Immunology       Date:  2000-03       Impact factor: 7.397

2.  Diverse apoptotic pathways in enterovirus 71-infected cells.

Authors:  Shih-Cheng Chang; Jing-Yi Lin; Lily Yen-cheng Lo; Mei-Ling Li; Shin-Ru Shih
Journal:  J Neurovirol       Date:  2004-12       Impact factor: 2.643

Review 3.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

4.  Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy.

Authors:  Paul Hatfield; Alison E Merrick; Emma West; Dearbhaile O'Donnell; Peter Selby; Richard Vile; Alan A Melcher
Journal:  J Immunother       Date:  2008-09       Impact factor: 4.456

Review 5.  The role of macrophage phenotype in regulating the response to radiation therapy.

Authors:  Xiaoshan Shi; Stephen L Shiao
Journal:  Transl Res       Date:  2017-11-20       Impact factor: 7.012

6.  A hyperfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon.

Authors:  Maria D Gainey; Mary J Manuse; Griffith D Parks
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103

Review 7.  Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

Authors:  Michael B Bernstein; Sunil Krishnan; James W Hodge; Joe Y Chang
Journal:  Nat Rev Clin Oncol       Date:  2016-03-08       Impact factor: 66.675

8.  Protease-activated receptor-2 signaling triggers dendritic cell development.

Authors:  Ryan C Fields; Jonathan G Schoenecker; Justin P Hart; Maureane R Hoffman; Salvatore V Pizzo; Jeffrey H Lawson
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

9.  Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.

Authors:  F Errington; C L White; K R Twigger; A Rose; K Scott; L Steele; L J Ilett; R Prestwich; H S Pandha; M Coffey; P Selby; R Vile; K J Harrington; A A Melcher
Journal:  Gene Ther       Date:  2008-04-10       Impact factor: 5.250

10.  Randomized phase II clinical trial of chemo-immunotherapy in advanced nonsmall cell lung cancer.

Authors:  Eduardo Lasalvia-Prisco; Emilio Garcia-Giralt; Jesús Vázquez; Marta Aghazarian; Eduardo Lasalvia-Galante; Joshemaria Larrañaga; Gonzalo Spera
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.